Wednesday, July 28, 2010

Neuroprotective properties of a novel, non-haematopoietic agonist of the erythropoietin receptor

Brain 2010 133(8):2281-2294; doi:10.1093/brain/awq101

Stanislava Pankratova1, Darya Kiryushko1, Katrin Sonn2, Vladislav Soroka1, Lene B. Køhler1, Mette Rathje1, Bing Gu1, Kamil Gotfryd1, Ole Clausen1, Alexander Zharkovsky2, Elisabeth Bock1 and Vladimir Berezin1

1 Protein Laboratory, Department of Neuroscience and Pharmacology, University of Copenhagen, 2200 Copenhagen, Denmark 2 Department of Pharmacology, Centre of Excellence for Translational Medicine, University of Tartu, 51014 Tartu, Estonia

Keywords: Erythropoietin, central nervous system, neuroprotective agent, non-haematopoietic erythropoietin, Epotris, neurite outgrowth, blood–brain barrier, neurodegeneration, neurological disorders.

Tuesday, July 27, 2010

First causal treatment option for Friedreich's Ataxia via Erythropoietin (EPO)

Technology collaboration OFFER
Abstract
An Austrian university offers the first treatment option for Friedreich´s Ataxia (FRDA), an inherited neurodegenerative disease. It causally targets FRDA
using Erythropoietin (EPO) to increase the level of Frataxin, decreased levels of which are reportedly responsible for the development of FRDA. So far
no other effective treatment is available which is at an advanced development stage. Industrial partners for further developing & commercialising
EPO for the treatment of FRDA are sought.

Date de creation: 23 July 2010

Thursday, July 22, 2010

Insulin signaling meets mitochondria in metabolism.

Trends Endocrinol Metab (2010), Published by Elsevier Ltd. DOI: 10.1016/j.tem.2010.06.005

Zhiyong Cheng, Yolanda Tseng and Morris F White
Howard Hughes Medical Institute, Division of Endocrinology, Children's Hospital Boston, Harvard Medical School, Boston MA, USA.

"chronic exposure to high ROS levels could alter mitochondrial function and thereby cause insulin resistance"

Tuesday, July 20, 2010

Klinik und Genetik der rezessiven Ataxien -[Clinical details and genetics of recessive ataxias.]

Nervenarzt. 2010 Jul 18. DOI: 10.1007/s00115-010-3079-4

Kühlke C, Kreuz F, Bürk K.

Institut für Humangenetik, Universität zu Lübeck.
[Article in German]

Monday, July 19, 2010

Iron-Sulfur (Fe-S) Cluster Assembly THE SufBCD COMPLEX IS A NEW TYPE OF Fe-S SCAFFOLD WITH A FLAVIN REDOX COFACTOR*

J. Biol. Chem. 2010 285: 23331-23341. First Published on May 11, 2010, doi:10.1074/jbc.M110.127449

Silke Wollers, Gunhild Layer, Ricardo Garcia-Serres, Luca Signor, Martin Clemancey, * Jean-Marc Latour, Marc Fontecave, and Sandrine Ollagnier de Choudens

Sunday, July 18, 2010

ArmaGen® Re-engineers Erythropoietin For Brain Penetration

Medical News Today, Article Date: 17 Jul 2010

"EPO drug development for the brain is limited, because EPO does not cross the blood-brain barrier (BBB)"

"EPO-driven neuroprotection in human brain disorders is now possible with systemic administration of the HIRMAb-EPO fusion protein at doses that have minimal effects on erythropoiesis."

ArmaGen® Web

Thursday, July 15, 2010

Oxidative stress, thiol redox signaling methods in epigenetics.

Methods Enzymol. 2010; 474: 213-44, doi:10.1016/S0076-6879(10)74013-1

Sundar IK, Caito S, Yao H, Rahman I

Keywords: Epigenetics, gene expression, posttranslational modifications, histones, histone acetylation, deacetylation, methylation, histone acetyltransferases (HATs), histone deacetylases (HDACs), reative oxygen species (ROS), signaling pathways, SIRT1.

Tuesday, July 13, 2010

Heterochromatin dysregulation in human diseases

J Appl Physiol 109: 232-242, 2010.
doi:10.1152/japplphysiol.00053.2010 

Matthias Hahn,* Silvia Dambacher,* and Gunnar Schotta
Munich Center for Integrated Protein Science (CiPSM) and Adolf-Butenandt-Institute, Ludwig-Maximilians-University, Munich, Germany 

Keywords: epigenetics, heterochromatin, epigenetic therapy, FSHD, Friedreich's ataxia (FRDA), cancer

Sunday, July 11, 2010

The Intermembrane Space of Mitochondria

Antioxidants & Redox Signaling.  doi:10.1089/ars.2009.3063.

Johannes M. Herrmann and Jan Riemer
Department of Cell Biology, University of Kaiserslautern, Kaiserslautern, Germany.

Saturday, July 10, 2010

Review: Friedreich Ataxia and Erythropoietin

The Open Drug Discovery Journal, Volume 2, ISSN: 1877-3818
Review: Friedreich Ataxia and Erythropoietin, pp.18-24 (7)
Authors: Sylvia Boesch, Brigitte Sturm, Wolfgang Nachbauer, Sascha Hering, Hannes Steinkellner, Rainer Schneider, Werner Poewe, Barbara Scheiber-Mojdehkar
doi: 10.2174/1877381801002020018
FULL TEXT PDF